Literature DB >> 6746651

Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores.

P Casellas, B J Bourrie, P Gros, F K Jansen.   

Abstract

The kinetics of cytotoxicity induced by ricin and a series of immunotoxins consisting of ricin A-chain coupled to antibodies against cell-surface antigens has been studied. The inhibition of protein synthesis in cells treated with immunotoxins or ricin occurs after a lag period. The rate of protein synthesis decreases according to a mono-exponential function, indicating a first-order process. With increasing concentration of immunotoxin, a maximal rate of inhibition is reached. The inactivation rate induced by immunotoxins was much slower than that achieved with ricin, even when products were compared on a basis of an identical number of molecules bound per cell, demonstrating the real higher efficacy of ricin. The time required to reduce protein synthesis by 90%, denoted T10, was 1.4-1.6 h with ricin, 60 h with anti-T65 immunotoxin on CEM human T leukemia cells (T65 positive), 65 h with anti-p97 immunotoxin on SK-MEL 28 human melanoma cells (p97 positive), and 20 h with an IgM anti-Thy 1.2 immunotoxin on WEHI-7 mouse T leukemia cells (Thy 1.2 positive). In this latter case, when the IgM antibody was replaced by an IgG anti-Thy 1.2, a 5-fold increase in the inactivation rate was obtained, demonstrating the importance of the binding moiety for the immunotoxins. Lysosomotropic amines such as ammonium chloride, chloroquine, and methylamine and carboxylic ionophores such as monensin, which are known to interfere with the uptake of certain macromolecules, strongly increased the rate of protein synthesis inhibition by all immunotoxins tested and increased 4-50,000-fold the sensitivity of cells to the immunotoxin. Enhancement in the inactivation rate was as much as 7-10-fold when either of these compounds was added, generating T10 values comparable to those of ricin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6746651

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  Targeting antibodies to the cytoplasm.

Authors:  Andrea L J Marschall; André Frenzel; Thomas Schirrmann; Manuela Schüngel; Stefan Dübel
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

2.  Induction and increase of HLA-DR antigen expression by immune interferon on ML-3 cell line enhances the anti-HLA-DR immunotoxin activity.

Authors:  M Chiron; J P Jaffrezou; P Carayon; C Bordier; F Roubinet; C Xavier; M Brandely; G Laurent
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

Review 3.  Monoclonal antibodies. Future potential in cancer chemotherapy.

Authors:  C Kosmas; H Kalofonos; A A Epenetos
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

4.  The in-vitro inhibition of rat alloantigen presentation by immunotoxins--implications for allografting.

Authors:  K N Wiley; A Clark; M Fox
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

5.  In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain.

Authors:  O Rostaing-Capaillon; P Casellas
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2.

Authors:  K Mujoo; R A Reisfeld; L Cheung; M G Rosenblum
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 7.  Monoclonal antibody targeting of anti-cancer agents.

Authors:  R W Baldwin; V S Byers
Journal:  Springer Semin Immunopathol       Date:  1986

8.  Different cytotoxic activity and intracellular fate of an anti-CD5-momordin immunotoxin in normal compared to tumour cells.

Authors:  G Porro; P Lento; F Marcucci; G Gromo; D Modena
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

9.  Characterization of the increased cytotoxicity of gelonin anti-T cell immunoconjugates compared with ricin A chain immunoconjugates.

Authors:  D M Fishwild; H M Wu; S F Carroll; S L Bernhard
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

10.  Internalization of an intact doxorubicin immunoconjugate.

Authors:  L B Shih; D M Goldenberg; H Xuan; H W Lu; M J Mattes; T C Hall
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.